Sign In
Buy ELEV
$0.365
+0 (+0%)
At Close: Oct 22, 2025
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
07:30am, Thursday, 02'nd May 2024
-- Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan; expect to announce initial safety and efficacy data by mid-3Q 2024, with additional data in 1H 2025 -- -- Presented pr
Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)
11:00am, Monday, 22'nd Apr 2024
Elevation Oncology, Inc. has had a successful year, transitioning from the shelving of their seribantumab program to focusing on antibody-drug conjugates. Their flagship project, EO-3021, is a phase 1
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
04:30pm, Monday, 08'th Apr 2024
-- On-track to nominate development candidate in 2024 -- BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and deve
All Three of Our Analysts Agree
08:02pm, Friday, 08'th Mar 2024
Personalized health screening from a “smart toilet”
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
07:30am, Wednesday, 06'th Mar 2024
--Expanded ongoing Phase 1 clinical trial of EO-3021 globally, dosing first patient in Japan; on track to provide update in mid-2024 and to report additional data in 1H 2025 -- -- Preclinical proof-of
Trim the Fat: 3 Overbought Stocks Poised for a Pullback
06:00pm, Tuesday, 05'th Mar 2024
Recently, I watched portions of a YouTube video that tangentially but importantly related to overbought stocks to sell. An options trader boasted about an 80% success rate with his system, which sound
-- Data support ongoing development of antibody-drug conjugate (ADC) program targeting HER3-expressing cancers – -- On-track to nominate development candidate in 2024 -- BOSTON , March 5, 2024 /PRNe
Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D.
07:30am, Monday, 04'th Mar 2024
BOSTON , March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients
PHILADELPHIA , Feb. 29, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Elevation Oncology, Inc. (NYSE: ELEV) on behalf of the company's investors. The investigation seeks to d
Elevation Oncology to Participate in Upcoming Investor Conferences
07:30am, Wednesday, 28'th Feb 2024
BOSTON , Feb. 28, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients
3 Stock Winners That Are Up 400% or More in 2024
09:17am, Friday, 23'rd Feb 2024
The stock market has seen a remarkable surge in recent months, climbing 21% since the end of October. Rallies as strong as this one tend to yield several stock winners, which in this case are primaril
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
07:30am, Thursday, 22'nd Feb 2024
-- On track to provide update from ongoing Phase 1 clinical trial in mid-2024; additional data expected in 1H 2025 -- BOSTON , Feb. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an
Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors
07:30am, Monday, 22'nd Jan 2024
BOSTON , Jan. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients
Elevation Oncology Announces Program Updates and Upcoming 2024 Milestones
07:30am, Friday, 05'th Jan 2024
-- Update from Ongoing Phase 1 Clinical Trial of EO-3021 Now Expected Mid-2024 -- -- Expanding EO-3021 Clinical Development Program to Include Combination Strategy -- -- Announcing HER3-targeting AD
Elevation Oncology to Present at the Piper Sandler 35th Annual Healthcare Conference
07:30am, Wednesday, 22'nd Nov 2023
BOSTON , Nov. 22, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients
